Wechselwirkungen · Suliqua
Suliqua 100 units/ml + 50 micrograms/ml solution for injection in pre-filled pen Suliqua 100 units/ml + 33 micrograms/ml solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 8
HOS-136780 · Präparat HOS-097920
Administration of the oral contraceptive 1 hour before or 4 hours after lixisenatide did not affect AUC and t1/2 of ethinylestradiol and levonorgestrel, whereas Cmax of ethinylestradiol was decreased by 52% and 39%, respectively and Cmax of levonorgestrel was decreased by 46% and 20%, respectively and median tmax was delayed by 1 to 3 hours. The reduction in Cmax is of limited clinical relevance and no dose adjustment for oral contraceptives is required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): levonorgestrel (HOS-089677)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T12:17:00Z · SHA-256 dc49151049b984e91c1de4b6624055f9c88998d89821408c31acf9bbdf9d1734 · Passage f3660f5baeda1d56a2270400f43524b9169b2e230cb0b9f033b10d4f75601c7e · Zeichen 4134–4592 im Abschnitt